Clinical outcome and management of ureteral obstruction secondary to gastric cancer. 2011

Kazuhiro Migita, and Akihiko Watanabe, and Shoji Samma, and Takao Ohyama, and Hirofumi Ishikawa, and Yoriaki Kagebayashi
Department of Surgery, Nara Prefectural Nara Hospital, 1-30-1 Hiramatsu, Nara, 631-0846, Japan. kmigita522@yahoo.co.jp7

BACKGROUND The clinical outcome of ureteral obstruction secondary to gastric cancer remains unclear. The present study was designed to evaluate the clinical outcome and predictive factors of survival in patients with ureteral obstruction secondary to gastric cancer. METHODS Twenty-five consecutive patients with ureteral obstruction secondary to gastric cancer between January 1998 and December 2007 were retrospectively analyzed. All patients had hydronephrosis; 13 patients had bilateral hydronephrosis, and 12 patients had unilateral hydronephrosis. RESULTS Ten patients presented with pain, 3 patients with urinary tract infection, and 2 patients with acute renal failure. Seven (58%) of 12 patients with unilateral ureteral obstruction experienced progression to bilateral ureteral obstruction during the follow-up period. Eighteen patients (61%) were eventually managed with urinary diversion. In total, 5 patients were managed with percutaneous nephrostomy, and 15 patients with retrograde ureteral stenting. All symptomatic patients responded to urinary diversion. The overall median survival was 5.8 months, and the 6-month and 1-year survival rates were 48 and 32%, respectively. Chemotherapy was found to be the only independent predictor of survival (p=0.0498). Median survival in patients who received chemotherapy was 11.2 months, in comparison to 3.1 months in patients who did not receive chemotherapy (p=0.0002). CONCLUSIONS The prognosis of ureteral obstruction secondary to gastric cancer was extremely poor, particularly when chemotherapy was not administered. The indications for palliative urinary diversion should be determined after considering the patient's symptoms, the expected survival time, the possibility of further chemotherapeutic options, and the current quality of life.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010166 Palliative Care Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed) Palliative Treatment,Palliative Supportive Care,Palliative Surgery,Palliative Therapy,Surgery, Palliative,Therapy, Palliative,Care, Palliative,Palliative Treatments,Supportive Care, Palliative,Treatment, Palliative,Treatments, Palliative
D010537 Peritoneum A membrane of squamous EPITHELIAL CELLS, the mesothelial cells, covered by apical MICROVILLI that allow rapid absorption of fluid and particles in the PERITONEAL CAVITY. The peritoneum is divided into parietal and visceral components. The parietal peritoneum covers the inside of the ABDOMINAL WALL. The visceral peritoneum covers the intraperitoneal organs. The double-layered peritoneum forms the MESENTERY that suspends these organs from the abdominal wall. Parietal Peritoneum,Peritoneum, Parietal,Peritoneum, Visceral,Visceral Peritoneum,Parametrium,Parametriums
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

Kazuhiro Migita, and Akihiko Watanabe, and Shoji Samma, and Takao Ohyama, and Hirofumi Ishikawa, and Yoriaki Kagebayashi
January 1974, The Johns Hopkins medical journal,
Kazuhiro Migita, and Akihiko Watanabe, and Shoji Samma, and Takao Ohyama, and Hirofumi Ishikawa, and Yoriaki Kagebayashi
September 1999, Journal of endourology,
Kazuhiro Migita, and Akihiko Watanabe, and Shoji Samma, and Takao Ohyama, and Hirofumi Ishikawa, and Yoriaki Kagebayashi
January 1982, The Journal of urology,
Kazuhiro Migita, and Akihiko Watanabe, and Shoji Samma, and Takao Ohyama, and Hirofumi Ishikawa, and Yoriaki Kagebayashi
February 2003, Surgical endoscopy,
Kazuhiro Migita, and Akihiko Watanabe, and Shoji Samma, and Takao Ohyama, and Hirofumi Ishikawa, and Yoriaki Kagebayashi
October 2001, Journal of endourology,
Kazuhiro Migita, and Akihiko Watanabe, and Shoji Samma, and Takao Ohyama, and Hirofumi Ishikawa, and Yoriaki Kagebayashi
November 1952, Southern medical journal,
Kazuhiro Migita, and Akihiko Watanabe, and Shoji Samma, and Takao Ohyama, and Hirofumi Ishikawa, and Yoriaki Kagebayashi
August 1985, Fertility and sterility,
Kazuhiro Migita, and Akihiko Watanabe, and Shoji Samma, and Takao Ohyama, and Hirofumi Ishikawa, and Yoriaki Kagebayashi
November 1981, The American surgeon,
Kazuhiro Migita, and Akihiko Watanabe, and Shoji Samma, and Takao Ohyama, and Hirofumi Ishikawa, and Yoriaki Kagebayashi
November 1969, The Journal of urology,
Kazuhiro Migita, and Akihiko Watanabe, and Shoji Samma, and Takao Ohyama, and Hirofumi Ishikawa, and Yoriaki Kagebayashi
August 1988, Urology,
Copied contents to your clipboard!